8-K Announcements
6Material company update
Apr 21, 2026·SEC
Material company update
Apr 14, 2026·SEC
Material company update
Mar 5, 2026·SEC
Aligos Therapeutics, Inc.(ALGS)Earnings, Financials & Key Ratios
ALGS•NASDAQ
$6.37
$39M mkt cap·Price updated May 6, 2026
AboutAligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.Show more
- Revenue$2M-44.6%
- EBITDA-$87M-0.6%
- Net Income-$24M+81.6%
- EPS (Diluted)-2.45+88.3%
- Gross Margin57.46%-42.5%
- EBITDA Margin-3982.39%-81.6%
- Operating Margin-4024.93%-78.1%
- Net Margin-1106.72%+66.7%
- ROE-196.92%+52.6%
- ROIC-162.97%
- Debt/Equity0.10
ALGS Key Insights
Aligos Therapeutics, Inc. (ALGS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y profit CAGR of 25.9%
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 1.2x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 14 (bottom 14%)
- ✗Shares diluted 57.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ALGS Price & Volume
Aligos Therapeutics, Inc. (ALGS) stock price & volume — 10-year historical chart
Loading chart...
ALGS Growth Metrics
Aligos Therapeutics, Inc. (ALGS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-46.03%
TTM-44.59%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM81.56%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM51.14%
Return on Capital
10 Years-70.28%
5 Years-89.8%
3 Years-108.85%
Last Year-152.15%
ALGS Peer Comparison
Aligos Therapeutics, Inc. (ALGS) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARWR | 11.08B | 79.14 | -6486.89 | 232.58% | 18.54% | 35.64% | 0.73 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 GILD | 169.83B | 136.30 | 358.68 | 6.04% | 28.9% | 37.62% | 1.39 | |
 VRTX | 108.78B | 427.65 | 27.91 | 9.57% | 35.4% | 23.93% | 0.21 | |
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 0.09 | |
 MDGL | 12.38B | 539.73 | -42.00 | 432.05% | -27.32% | -50.15% | 0.59 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 |
Compare ALGS vs Peers
Aligos Therapeutics, Inc. (ALGS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALGS Income Statement
Aligos Therapeutics, Inc. (ALGS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 4.36M | 13.91M | 15.53M | 3.94M | 2.19M |
| Revenue Growth % | - | - | - | - | 219.04% | 11.66% | -74.6% | -44.59% |
| Cost of Goods Sold | 1.29M | 2.3M | 3.33M | 0 | 0 | 0 | 0 | 930K |
| COGS % of Revenue | - | - | - | - | - | - | - | 42.54% |
| Gross Profit | -1.29M▲ 0% | -2.3M▼ 78.1% | -3.33M▼ 44.6% | 4.36M▲ 231.1% | 13.91M▲ 219.0% | 15.53M▲ 11.7% | 3.94M▼ 74.6% | 1.26M▼ 68.2% |
| Gross Margin % | - | - | - | 100% | 100% | 100% | 100% | 57.46% |
| Gross Profit Growth % | - | -78.08% | -44.63% | 231.1% | 219.04% | 11.66% | -74.6% | -68.16% |
| Operating Expenses | 13.66M | 54.04M | 94.51M | 132.68M | 111.49M | 103.66M | 93.1M | 89.24M |
| OpEx % of Revenue | - | - | - | 3043.82% | 801.66% | 667.5% | 2359.92% | 4082.39% |
| Selling, General & Admin | 3.21M | 10.01M | 14.62M | 28.53M | 26.41M | 30.62M | 22.83M | 20.72M |
| SG&A % of Revenue | - | - | - | 654.44% | 189.9% | 197.15% | 578.71% | 947.76% |
| Research & Development | 10.46M | 44.04M | 79.89M | 104.15M | 85.08M | 73.04M | 70.27M | 69.45M |
| R&D % of Revenue | - | - | - | 2389.38% | 611.76% | 470.35% | 1781.22% | 3177.17% |
| Other Operating Expenses | -435K | 302K | 0 | 0 | 0 | 0 | 0 | -930K |
| Operating Income | -13.66M▲ 0% | -54.04M▼ 295.6% | -97.83M▼ 81.0% | -128.32M▼ 31.2% | -97.58M▲ 24.0% | -88.13M▲ 9.7% | -89.15M▼ 1.2% | -87.98M▲ 1.3% |
| Operating Margin % | - | - | - | -2943.82% | -701.66% | -567.5% | -2259.92% | -4024.93% |
| Operating Income Growth % | - | -295.6% | -81.03% | -31.16% | 23.96% | 9.69% | -1.17% | 1.31% |
| EBITDA | -12.37M | -51.74M | -94.51M | -124.54M | -93.91M | -85.06M | -86.53M | -87.06M |
| EBITDA Margin % | - | - | - | -2857.15% | -675.24% | -547.74% | -2193.46% | -3982.39% |
| EBITDA Growth % | - | -318.3% | -82.65% | -31.78% | 24.6% | 9.42% | -1.73% | -0.6% |
| D&A (Non-Cash Add-back) | 1.29M | 2.3M | 3.33M | 3.78M | 3.67M | 3.07M | 2.62M | 930K |
| EBIT | -13.66M | -52.18M | -108.38M | -128.32M | -97.58M | -88.13M | -89.15M | -87.98M |
| Net Interest Income | 0 | 1.86M | -9.29M | 132K | 1.64M | 1.24M | 1.67M | 2.16M |
| Interest Income | 163K | 1.86M | 1.26M | 132K | 1.64M | 1.24M | 1.67M | 2.16M |
| Interest Expense | 0 | 0 | 10.55M | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -272K | 1.86M | -10.55M | 132K | 1.64M | 1.24M | -41.73M | 64.11M |
| Pretax Income | -13.93M▲ 0% | -52.18M▼ 274.5% | -108.38M▼ 107.7% | -128.19M▼ 18.3% | -95.94M▲ 25.2% | -86.88M▲ 9.4% | -130.88M▼ 50.6% | -23.88M▲ 81.8% |
| Pretax Margin % | - | - | - | -2940.79% | -689.87% | -559.5% | -3317.62% | -1092.36% |
| Income Tax | 0 | 85K | 161K | 143K | 106K | 795K | 331K | 314K |
| Effective Tax Rate % | 0% | -0.16% | -0.15% | -0.11% | -0.11% | -0.92% | -0.25% | -1.31% |
| Net Income | -13.93M▲ 0% | -52.26M▼ 275.1% | -108.54M▼ 107.7% | -128.33M▼ 18.2% | -96.05M▲ 25.2% | -87.68M▲ 8.7% | -131.21M▼ 49.6% | -24.19M▲ 81.6% |
| Net Margin % | - | - | - | -2944.07% | -690.63% | -564.61% | -3326.01% | -1106.72% |
| Net Income Growth % | - | -275.11% | -107.68% | -18.23% | 25.16% | 8.71% | -49.65% | 81.56% |
| Net Income (Continuing) | -13.93M | -52.26M | -108.54M | -128.33M | -96.05M | -87.68M | -131.21M | -24.19M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.66▲ 0% | -2.38▼ 260.6% | -3.18▼ 33.6% | -3.22▼ 1.3% | -2.25▲ 30.1% | -3.52▼ 56.4% | -20.94▼ 494.9% | -2.45▲ 88.3% |
| EPS Growth % | - | -260.61% | -33.61% | -1.26% | 30.12% | -56.44% | -494.89% | 88.3% |
| EPS (Basic) | -0.66 | -2.38 | -3.18 | -3.22 | -2.25 | -3.52 | -20.94 | -2.45 |
| Diluted Shares Outstanding | 21.17M | 21.93M | 34.18M | 39.86M | 42.7M | 24.87M | 6.26M | 9.88M |
| Basic Shares Outstanding | 21.17M | 21.93M | 34.18M | 39.86M | 42.7M | 24.87M | 6.26M | 9.88M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
ALGS Balance Sheet
Aligos Therapeutics, Inc. (ALGS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 92.37M | 120.23M | 250.02M | 204.42M | 133.54M | 141.08M | 62.14M | 82.86M |
| Cash & Short-Term Investments | 90.85M | 117.66M | 243.51M | 190.73M | 125.83M | 135.7M | 56.94M | 77.84M |
| Cash Only | 24.04M | 69.56M | 220.38M | 186.82M | 81.35M | 135.7M | 37M | 18.3M |
| Short-Term Investments | 66.82M | 48.1M | 23.13M | 3.92M | 44.48M | 0 | 19.94M | 59.54M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 1.52M | 2.56M | 6.5M | 13.69M | 7.72M | 5.38M | 5.2M | 5.02M |
| Total Non-Current Assets | 15.36M | 26.29M | 15.29M | 30.95M | 13.15M | 10.44M | 7.95M | 5.67M |
| Property, Plant & Equipment | 15.18M | 16.09M | 14.91M | 14.97M | 12.51M | 9.82M | 7.33M | 4.96M |
| Fixed Asset Turnover | - | - | - | 0.29x | 1.11x | 1.58x | 0.54x | 0.44x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 10.02M | 0 | 15.11M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 178K | 188K | 377K | 866K | 634K | 625K | 627K | 715K |
| Total Assets | 107.73M▲ 0% | 146.52M▲ 36.0% | 265.3M▲ 81.1% | 235.37M▼ 11.3% | 146.69M▼ 37.7% | 151.53M▲ 3.3% | 70.09M▼ 53.7% | 88.53M▲ 26.3% |
| Asset Turnover | - | - | - | 0.02x | 0.09x | 0.10x | 0.06x | 0.02x |
| Asset Growth % | - | 36.01% | 81.07% | -11.28% | -37.68% | 3.3% | -53.74% | 26.31% |
| Total Current Liabilities | 7.49M | 13.82M | 30.27M | 38.96M | 33.13M | 23.91M | 21.74M | 21.23M |
| Accounts Payable | 2.98M | 3.77M | 3.31M | 3.02M | 4.74M | 2.52M | 2.57M | 3.98M |
| Days Payables Outstanding | 841.68 | 598.07 | 363.68 | - | - | - | - | 1.56K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 3.18M | 0 | 7.89M | 7.64M | 9.21M | 1.31M | 151K | 0 |
| Other Current Liabilities | 272K | 3.96M | 7.84M | 6.61M | 6.36M | 6.67M | 6.39M | 13.53M |
| Current Ratio | 12.33x | 8.70x | 8.26x | 5.25x | 4.03x | 5.90x | 2.86x | 3.90x |
| Quick Ratio | 12.33x | 8.70x | 8.26x | 5.25x | 4.03x | 5.90x | 2.86x | 3.90x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 113.99M | 197.59M | 14.99M | 11.68M | 9.66M | 35.54M | 79.09M | 14.8M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 12.61M | 11.88M | 10.5M | 11.55M | 9.43M | 7.9M | 4.92M | 1.52M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 1.76M | 1.05M |
| Other Non-Current Liabilities | 101.38M | 185.71M | 379K | 133K | 0 | 27.64M | 72.41M | 12.23M |
| Total Liabilities | 121.48M | 211.41M | 45.26M | 50.64M | 42.79M | 59.45M | 99.07M | 34.99M |
| Total Debt | 13.86M | 14.33M | 13.01M | 14.46M | 12.57M | 11.14M | 8.38M | 5.25M |
| Net Debt | -10.17M | -55.23M | -207.38M | -172.36M | -68.77M | -124.57M | -28.62M | -13.05M |
| Debt / Equity | - | - | 0.06x | 0.08x | 0.12x | 0.12x | - | 0.10x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -10.28x | - | - | - | - | - |
| Total Equity | -13.75M▲ 0% | -64.89M▼ 372.0% | 220.04M▲ 439.1% | 184.73M▼ 16.0% | 103.9M▼ 43.8% | 92.08M▼ 11.4% | -28.97M▼ 131.5% | 53.55M▲ 284.8% |
| Equity Growth % | - | -372% | 439.09% | -16.05% | -43.76% | -11.38% | -131.47% | 284.81% |
| Book Value per Share | -0.65 | -2.96 | 6.44 | 4.64 | 2.43 | 3.70 | -4.62 | 5.42 |
| Total Shareholders' Equity | -13.75M | -64.89M | 220.04M | 184.73M | 103.9M | 92.08M | -28.97M | 53.55M |
| Common Stock | 3K | 0 | 4K | 4K | 4K | 7K | 8K | 9K |
| Retained Earnings | -13.93M | -66.2M | -174.74M | -303.07M | -399.12M | -486.8M | -618.01M | -642.2M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 3K | -115K | -188K | 452K | 401K | 545K | 451K | 468K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ALGS Cash Flow Statement
Aligos Therapeutics, Inc. (ALGS) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -6.05M | -46.77M | -74.26M | -115.66M | -79.39M | -79M | -80.74M | -82.5M |
| Operating CF Margin % | - | - | - | -2653.41% | -570.86% | -508.71% | -2046.72% | -3774.15% |
| Operating CF Growth % | - | -673.14% | -58.79% | -55.75% | 31.36% | 0.49% | -2.21% | -2.18% |
| Net Income | -13.93M | -52.26M | -108.54M | -128.33M | -96.05M | -87.68M | -131.21M | -24.19M |
| Depreciation & Amortization | 1.29M | 2.3M | 3.33M | 3.78M | 3.67M | 3.07M | 2.62M | 930K |
| Stock-Based Compensation | 179K | 752K | 2.98M | 13.46M | 14.69M | 12.65M | 8.45M | 5.04M |
| Deferred Taxes | -110K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.64M | -1.23M | 11.92M | 86K | -159K | 2.49M | 44.35M | -60.5M |
| Working Capital Changes | 4.88M | 3.67M | 16.06M | -4.65M | -1.55M | -9.53M | -4.96M | -3.79M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 2.98M | 385K | -130K | -313K | 1.72M | -2.22M | 54K | 1.41M |
| Cash from Investing | -69.29M | 6.79M | 32.76M | 3.02M | -26.29M | 44.98M | -18.28M | -37.83M |
| Capital Expenditures | -2.52M | -2.79M | -2.06M | -892K | -943K | -19K | -130K | -437K |
| CapEx % of Revenue | - | - | - | 20.46% | 6.78% | 0.12% | 3.3% | 19.99% |
| Acquisitions | 0 | 0 | 0 | -3.91M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -72.84M | 0 | 0 | 3.91M | 0 | 0 | 0 | 0 |
| Cash from Financing | 99.89M | 85.53M | 192.35M | 78.68M | 164K | 88.33M | 355K | 101.64M |
| Debt Issued (Net) | 5M | -43K | -58K | -79K | -61K | -96K | -83K | -14K |
| Equity Issued (Net) | 94.81M | 84.96M | 195.54M | 78.58M | 225K | 17.44M | 438K | 101.65M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 77K | 612K | -3.14M | 172K | 0 | 70.98M | 0 | 0 |
| Net Change in Cash | 24.55M▲ 0% | 45.56M▲ 85.6% | 150.84M▲ 231.1% | -33.96M▼ 122.5% | -105.52M▼ 210.7% | 54.31M▲ 151.5% | -98.67M▼ 281.7% | -18.69M▲ 81.1% |
| Free Cash Flow | -8.56M▲ 0% | -49.55M▼ 478.6% | -76.33M▼ 54.0% | -116.55M▼ 52.7% | -80.33M▲ 31.1% | -79.02M▲ 1.6% | -80.87M▼ 2.4% | -82.94M▼ 2.6% |
| FCF Margin % | - | - | - | -2673.87% | -577.64% | -508.83% | -2050.01% | -3794.14% |
| FCF Growth % | - | -478.55% | -54.03% | -52.7% | 31.08% | 1.64% | -2.35% | -2.56% |
| FCF per Share | -0.40 | -2.26 | -2.23 | -2.92 | -1.88 | -3.18 | -12.91 | -8.39 |
| FCF Conversion (FCF/Net Income) | 0.43x | 0.89x | 0.68x | 0.90x | 0.83x | 0.90x | 0.62x | 3.41x |
| Interest Paid | 0 | 6K | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
ALGS Key Ratios
Aligos Therapeutics, Inc. (ALGS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -139.92% | -63.41% | -66.55% | -89.48% | -415.84% | -196.92% |
| Return on Invested Capital (ROIC) | - | - | -579.45% | -768.91% | -308.17% | -5005.32% | - | -162.97% |
| Gross Margin | - | - | - | 100% | 100% | 100% | 100% | 57.46% |
| Net Margin | - | - | - | -2944.07% | -690.63% | -564.61% | -3326.01% | -1106.72% |
| Debt / Equity | - | - | 0.06x | 0.08x | 0.12x | 0.12x | - | 0.10x |
| Interest Coverage | - | - | -10.28x | - | - | - | - | - |
| FCF Conversion | 0.43x | 0.89x | 0.68x | 0.90x | 0.83x | 0.90x | 0.62x | 3.41x |
| Revenue Growth | - | - | - | - | 219.04% | 11.66% | -74.6% | -44.59% |
ALGS SEC Filings & Documents
Aligos Therapeutics, Inc. (ALGS) SEC filings — annual & quarterly reports (10-K, 10-Q)
ALGS Frequently Asked Questions
Aligos Therapeutics, Inc. (ALGS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Aligos Therapeutics, Inc. (ALGS) reported $2.2M in revenue for fiscal year 2025.
Aligos Therapeutics, Inc. (ALGS) saw revenue decline by 44.6% over the past year.
Aligos Therapeutics, Inc. (ALGS) reported a net loss of $24.2M for fiscal year 2025.
Dividend & Returns
Aligos Therapeutics, Inc. (ALGS) has a return on equity (ROE) of -196.9%. Negative ROE indicates the company is unprofitable.
Aligos Therapeutics, Inc. (ALGS) had negative free cash flow of $82.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More ALGS
Aligos Therapeutics, Inc. (ALGS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates